Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06287528
What this trial is testing

19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Philadelphia-Negative ALLPhiladelphia-Positive ALLRelapsed ALL, Adult+3 more
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT00244829
What this trial is testing

Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia

Who this might be right for
Leukemia
Fred Hutchinson Cancer Center
Not applicableStudy completedNCT00068523
What this trial is testing

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+3 more
Case Comprehensive Cancer Center 10
Testing effectiveness (Phase 2)Ended earlyNCT00723203
What this trial is testing

Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Who this might be right for
Leukemia
City of Hope Medical Center 16
Testing effectiveness (Phase 2)Study completedNCT01279473
What this trial is testing

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Who this might be right for
Chronic Myelogenous LeukemiaAcute Lymphoblastic Leukemia
Novartis Pharmaceuticals 42
Testing effectiveness (Phase 2)Looking for participantsNCT03739814
What this trial is testing

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Who this might be right for
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) 84
Testing effectiveness (Phase 2)Ended earlyNCT04501614
What this trial is testing

Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Who this might be right for
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)Ph+ Mixed Phenotype Acute Leukemia (MPAL)Philadelphia Chromosome-Like ALL (Ph-like ALL)
Takeda 11
Large-scale testing (Phase 3)Active Not RecruitingNCT03589326
What this trial is testing

Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Who this might be right for
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Takeda 245
Testing effectiveness (Phase 2)Study completedNCT01724879
What this trial is testing

Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

Who this might be right for
Philadelphia Positive Acute Lymphoblastic Leukemia
Goethe University 19
Early research (Phase 1)Active Not RecruitingNCT03233854
What this trial is testing

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Who this might be right for
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+1 more
Stanford University 56
Testing effectiveness (Phase 2)UnknownNCT02744768
What this trial is testing

D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 60
Not applicableEnded earlyNCT00608517
What this trial is testing

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
Vanderbilt-Ingram Cancer Center 6
Early research (Phase 1)Study completedNCT01159028
What this trial is testing

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

Who this might be right for
Recurrent Adult Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome+1 more
Bio-Path Holdings, Inc. 60
Large-scale testing (Phase 3)Study completedNCT01743989
What this trial is testing

Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

Who this might be right for
Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Novartis Pharmaceuticals 620
Testing effectiveness (Phase 2)Study completedNCT00171249
What this trial is testing

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Who this might be right for
Philadelphia Positive Chronic Myeloid LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia
Novartis Pharmaceuticals 293
Post-approval studies (Phase 4)Study completedNCT01735955
What this trial is testing

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Who this might be right for
Chronic Myelogenous Leukemia (CML)Metastatic Gastrointestinal Stromal Tumors (GIST)Acute Lymphoblastic Leukemia (ALL)+1 more
Novartis Pharmaceuticals 57
Testing effectiveness (Phase 2)UnknownNCT01361438
What this trial is testing

De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients

Who this might be right for
ALL Ph Positive
Gruppo Italiano Malattie EMatologiche dell'Adulto 60
Testing effectiveness (Phase 2)Looking for participantsNCT07387926
What this trial is testing

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Acute Lymphoblastic LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-PositivePhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals 50
Large-scale testing (Phase 3)Study completedNCT00265837
What this trial is testing

Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+3 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 72
Early research (Phase 1)Study completedNCT00588991
What this trial is testing

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Who this might be right for
Adult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic Leukemia+20 more
National Cancer Institute (NCI) 12
Next Page